Euda Health Holdings stock (US29821P1030): Nasdaq listing risk eases after compliance regained

Euda Health Holdings shares are trading on Nasdaq after the Singapore-based healthcare group disclosed it has regained compliance with the exchange’s minimum market value requirement, easing a recent listing overhang.

Euda Health Holdings, whose shares trade on the Nasdaq Capital Market under the ticker EUDA, has eased a key listing overhang after disclosing that it has regained compliance with Nasdaq’s minimum Market Value of Listed Securities requirement, according to a company announcement dated 05/28/2026 that was subsequently highlighted by outlets such as Investing.com and Quiver Quantitative. The company said Nasdaq notified it that its Market Value of Listed Securities had been at least USD 35 million for ten consecutive business days from 05/13/2026 through 05/27/2026, restoring the Singapore-based group’s eligibility for continued listing on the U.S. exchange.

The compliance update follows an earlier Nasdaq notice in April 2026, when the exchange flagged that Euda Health Holdings had fallen below the USD 35 million Market Value of Listed Securities threshold required for continued listing on the Nasdaq Capital Market. By meeting the standard for ten straight sessions, Euda Health Holdings has removed the immediate risk of delisting tied specifically to this metric, while remaining subject to Nasdaq’s ongoing listing criteria. As a healthcare stock listed in the United States, the group provides U.S. investors with exposure to a non-invasive healthcare provider whose core operations are located in Singapore and other parts of Asia.

The stock continued to trade on Nasdaq after the May notification, with the regained compliance underscoring the importance of overall market value for issuers on the exchange. While intraday trading data move constantly, the company’s ability to lift its Market Value of Listed Securities back to at least USD 35 million over a defined ten-day period was key to satisfying Nasdaq’s requirements for the Market Value of Listed Securities measure. In line with Nasdaq Capital Market rules, this threshold is calculated using the total value of the company’s listed shares, and is monitored daily by the exchange as part of its oversight of issuers.

For investors in the United States, the update on Nasdaq compliance is a reminder that listing standards extend beyond share price and include measures such as Market Value of Listed Securities, stockholders’ equity and corporate governance requirements. In Euda Health Holdings’ case, the company has confirmed that the specific deficiency cited in April 2026 relating to the Market Value of Listed Securities has now been resolved, based on the May 2026 notification from Nasdaq. This comes as the group continues to position itself as a non-invasive healthcare provider focused on Singapore, Malaysia and China, operating from its base in Singapore while accessing equity capital through the U.S. market.

On 06/01/2026, Euda Health Holdings also reported a product expansion in its Helixé portfolio, announcing the launch of a new Regenixé induced pluripotent stem cell-derived skin stem cell secretome mask, according to a press release distributed via Globe Newswire. The company, which holds exclusive global distributorship rights for Helixé products, stated that this launch adds another offering to its aesthetic and wellness-oriented product set, complementing its non-invasive healthcare services across Asia. The product update underscores that management is seeking to broaden the group’s revenue opportunities while maintaining its focus on non-invasive, technology-supported healthcare solutions.

As of: 02.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Euda Health Holdings
• Sector/industry: Non-invasive healthcare services and wellness products
• Headquarters/country: Singapore, Singapore
• Core markets: Singapore, Malaysia, China
• Key revenue drivers: Non-invasive healthcare services platform and distribution of Helixé-branded wellness and skincare products
• Home exchange/listing venue: Nasdaq Capital Market (EUDA)
• Trading currency: USD

Euda Health Holdings: core business model

Euda Health Holdings centers its business on delivering technology-enabled, non-invasive healthcare services across selected Asian markets while complementing this with the distribution of Helixé-branded wellness and skincare products that add another revenue stream to its platform.

Latest quarterly results for Euda Health Holdings at a glance

The most recent set of quarterly financial results available for Euda Health Holdings confirms that the company continues to report as a healthcare services and products provider focused on Asia, although detailed figures and segment disclosures were last formally summarized prior to the May 2026 Nasdaq compliance update and the June 2026 Helixé product expansion announcement. In those filings and related disclosures, the company described a business model tied to virtual and in-person non-invasive healthcare services, alongside its more recent wellness offerings under the Helixé brand, without releasing a new quarterly earnings report in the immediate days surrounding the May 2026 Nasdaq notification.

Given the absence of a brand-new quarterly earnings release dated in the same week as the May 2026 Nasdaq notification, investors currently evaluating Euda Health Holdings are primarily working with the last reported quarterly figures and looking ahead to the next scheduled results to assess the impact of newer initiatives such as the Regenixé stem cell secretome mask launch. Until a fresh quarterly statement is published, the regained Nasdaq compliance and the additional Helixé product serve as key qualitative data points alongside the company’s existing historical financial information, informing how market participants think about the group’s scale, growth potential and cost structure in the United States-listed healthcare segment.

Conclusion

Euda Health Holdings has addressed a recent Nasdaq listing concern by restoring compliance with the exchange’s USD 35 million Market Value of Listed Securities requirement, reducing the near-term risk of a delisting tied to that specific metric. At the same time, the company is working to widen its product mix through initiatives such as the new Regenixé stem cell secretome mask under the Helixé brand, which could influence how its non-invasive healthcare and wellness platform develops over time. The next set of quarterly results will be important for investors seeking to quantify how these operational and listing-related developments translate into revenue and profitability dynamics for the Nasdaq-listed Singapore healthcare group.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.